ATAI Life Sciences NV, in collaboration with Beckley Psytech, has announced positive results from a Phase 2b study of BPL-003, a psychedelic therapy aimed at treating patients with treatment-resistant depression. The study achieved its primary and secondary endpoints, demonstrating rapid and durable antidepressive effects with a single 8 mg or 12 mg dose, and favorable tolerability with minimal in-clinic time. These results support the advancement of BPL-003 into Phase 3 clinical studies. ATAI and Beckley Psytech plan to engage with the U.S. Food and Drug Administration and other regulatory agencies to discuss the design of the Phase 3 trial. A conference call and live webcast to discuss the findings will be held on July 1, 2025, and an archived replay will be available on ATAI's corporate website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.